Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026
Calidi Biotherapeutics announced it will present new preclinical data on its lead oncolytic virus candidate CLD-401 at the AACR Annual Meeting in April 2026. CLD-401, leveraging the proprietary RedTail platform, is designed for systemic delivery and tumor-specific expression of IL-15 superagonist to activate immune response within the tumor microen…